These results suggest that although the survival of these implanted grafts is reduced, it is secondary to extra-hepatic factors. Disclosures: The following people C646 mouse have nothing to disclose: Francis P. Robertson, Pulathis Siri-wardana, Paul R. Bessell, Rafael Diaz-Nieto, Nancy Rolando, Brian R. Davidson Background: Portal vein thrombosis (PVT) occurs in 3-7% of adult patients following orthotopic liver transplantation (OLT). The long term consequences and potential impact on graft and patient survival remain unknown. Methods: We identified seventeen

patients who underwent a liver transplant at our institution between January 2006 and December 2013 and developed PVT following OLT (PVT group) and compared their outcomes to those of 51 controls who had received a liver transplant during the same time period selleck products (non-PVT group). Controls were matched to cases on the basis of age, gender, body mass index (BMI) and etiology of liver disease. Graft survival was defined as time from transplantation to death, last follow-up or re-transplantation. Kaplan Meier survival analysis was used to compare graft and patient survival between both groups. Results: Baseline patient and donor characteristics were similar between both groups. There was no statistically significant difference in the incidence of biopsy proven acute or chronic rejection and biliary complications (anastomotic

and non-anastomotic strictures) between both groups. Seven 上海皓元医药股份有限公司 patients (41%) in the PVT group had esophageal and/or gastric varices detected endoscopically or on imaging, compared to 7/51 (14%) of patients in the control group (p=0.016). Variceal bleeding occurred in 12% of patients in the PVT group compared to 4% of patients in the control group (p=0.06). Clinically significant ascites occurred in 9/17 patients in the PVT group (53%) compared to 10/41 patients in the control group (19.6%) (p=0.0085). Overt hepatic encephalopathy occurred in 2/17 patients

in the PVT group (12%) compared to 1/51 (2%) of patients in the control group (p=0.09). Interestingly, patients in the PVT group were also more likely to develop hepatic artery thrombosis (HAT) compared to patients in the control group (23.5% vs 5.9% respectively; p= 0.04). Seven patients in the PVT group (41%) died compared to 11 in the control group (21%) (p=0.11). The main cause of death in both groups was sepsis, followed by cardiovascular disease and malignancy. There was no statistically significant difference in graft and patient survival between both groups. Mean duration of follow up was 976±707 days for the PVT group and 1187±728 days for the control group (p=0.3). Conclusion: New PVT following OLT did not impact graft or patient survival, however patients with PVT post transplantation were more likely to develop varices and clinically significant asci-tes. Variceal bleeding and hepatic encephalopathy occurred more frequently amongst PVT patients but the difference did not reach statistical significance.